Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19291477 | 1.00 | TAAR1 (0.53) | TAAR1LTA4HPLA2G2ASCN4ALMNA | |
| SCHEMBL2206118 | 1.00 | TAAR1 (0.53) | TAAR1LTA4HPLA2G2ASCN4ALMNA | |
| SCHEMBL15150952 | 0.88 | TAAR1 (0.53) | TAAR1LTA4HPLA2G2ATSHRMAPK1 | |
| SCHEMBL4568924 | 0.85 | KMT2A (0.51) | LMNATSHRMAPK1 | |
| SCHEMBL29818635 | 0.84 | LTA4H (0.43) | LTA4HSCN4A | |
| SCHEMBL2206536 | 0.84 | LTA4H (0.43) | LTA4HSCN4A | |
| SCHEMBL19291816 | 0.84 | LTA4H (0.43) | LTA4HSCN4A | |
| SCHEMBL10635980 | 0.81 | MAOB (0.54) | LTA4HSCN4ALMNATSHR | |
| SCHEMBL610432 | 0.80 | TAAR1 (0.47) | TAAR1LTA4HPLA2G2A | |
| SCHEMBL19291721 | 0.80 | CYP4F2 (0.44) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | TAAR1 1482/4885LTA4H 216/4885PLA2G2A 1526/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | TAAR1 1482/4885LTA4H 216/4885PLA2G2A 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.